Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug: report
By Jan Wolfe (Reuters) - A U.S. jury said on Monday that patents owned by Amgen Inc on its cholesterol drug Rapatha are valid, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA, Bloomberg reported. Sanofi and Regeneron had stipulated that if the Amgen patents were valid, their jointly developed cholesterol drug Praluent infringed them
By Jan Wolfe
(Reuters) - A U.S. jury said on Monday that patents owned by Amgen Inc on its cholesterol drug Rapatha are valid, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA, Bloomberg reported.
Related Articles
Sanofi and Regeneron had stipulated that if the Amgen patents were valid, their jointly developed cholesterol drug Praluent infringed them.
Thousand Oaks, California-based Amgen won a similar verdict in 2016, as well as a court order blocking Praluent sales, but an appeals court set aside the victory and ordered a new trial.
(Reporting by Jan Wolfe; Editing by Cynthia Osterman and Richard Chang)
This story has not been edited by Firstpost staff and is generated by auto-feed.
also read
South Korean woman linked to scandal to be extradited from Denmark - prosecutor | Reuters
COPENHAGEN A South Korean woman wanted for questioning in connection with the scandal that brought down president Park Geun-hye has withdrawn her appeal against extradition from Denmark, the Danish state prosecutor said on Wednesday.
Pope asks Trump to be peacemaker, gives him environmental letter | Reuters
By Philip Pullella and Steve Holland | VATICAN CITY VATICAN CITY Pope Francis urged U.S.
